Genespire is born of science and builds on pioneering work of Pr. Luigi Naldini in gene therapy.
At Genespire, we aim at curing patients suffering from severe medical conditions with next generation gene therapies based on our proprietary advanced lentiviral vector platforms. Our groundbreaking immune-shielding (ISLV) technology allows first-in-class in vivo application of lentiviral vectors in the liver. We further develop ex vivo gene therapies by combining integration-defective lentiviral vectors with gene editing (IDLV-GE) for high-efficacy and versatile targeted insertion of therapeutic genes in blood cells. We leverage the potential of these technologies and strive to bring them from the bench to the patient’s bedside, to change the life of people who are not offered appropriate medical solutions today.
Genespire is led by an experienced and international management team coming from renowned biotech companies and world-class biopharmaceutical organizations. The company is located in Milan, Italy, and was co-founded by Fondazione Telethon, Ospedale San Raffaele, Pr. Luigi Naldini and Dr. Alessio Cantore.